drugset / Trial / NCT06798623
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.
Timeline
- Start
- 2026-03-24
- Primary completion
- 2028-03
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Mesenchymal Stromal Cells | Cell therapy | 1.5 ml | Other |
| Subject | Autologous Mesenchymal Stromal Cells | Cell therapy | 5e+07 cells | Other |
Indications
No indication recorded.